During this webinar BioSpace sits down with former FDA Chief Information Officer Vid Desai to discuss the potential ...
In this episode presented by PII, BioSpace’s head of insights discusses decentralized clinical studies and how connected ...
An unnamed source clarified that Sandra Retzky has not been fired from the FDA, but it remains unclear where she was ...
Due largely to CSL, Merck and Novo Nordisk’s reorganizations that could total about 19,350 people, Q3 cuts rose significantly ...
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record ...
Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s ...
The company is pursuing a Phase III trial for its topical stem cell-rejuvenating molecule that aims to reactivate hair growth ...
Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene ...
After the FDA revoked Sarepta Therapeutics’ platform designation in July, Krystal Biotech is “poised to be the first major ...
Kailera’s lead asset, KAI-9531, elicited an average weight loss of more than 17% in a Phase III study in China. The biotech ...
Johnson & Johnson has yet to make a drug pricing deal with Trump; Novo makes more moves under new CEO; more than 1,000 laid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results